PortalPublikationenUpdate Breast Cancer 2019 Part 4 - Diagnostic and Therapeuti...

Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer

Standard

Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. / Schütz, Florian; Fasching, Peter A; Welslau, Manfred; Hartkopf, Andreas D; Wöckel, Achim; Lux, Michael P; Janni, Wolfgang; Ettl, Johannes; Lüftner, Diana; Belleville, Erik; Kolberg, Hans-Christian; Overkamp, Friedrich; Taran, Florin-Andrei; Brucker, Sara Y; Wallwiener, Markus; Tesch, Hans; Fehm, Tanja N; Schneeweiss, Andreas; Müller, Volkmar.

in: GEBURTSH FRAUENHEILK, Jahrgang 79, Nr. 10, 10.2019, S. 1079-1089.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schütz, F, Fasching, PA, Welslau, M, Hartkopf, AD, Wöckel, A, Lux, MP, Janni, W, Ettl, J, Lüftner, D, Belleville, E, Kolberg, H-C, Overkamp, F, Taran, F-A, Brucker, SY, Wallwiener, M, Tesch, H, Fehm, TN, Schneeweiss, A & Müller, V 2019, 'Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer', GEBURTSH FRAUENHEILK, Jg. 79, Nr. 10, S. 1079-1089. https://doi.org/10.1055/a-1001-9925

APA

Schütz, F., Fasching, P. A., Welslau, M., Hartkopf, A. D., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Lüftner, D., Belleville, E., Kolberg, H-C., Overkamp, F., Taran, F-A., Brucker, S. Y., Wallwiener, M., Tesch, H., Fehm, T. N., Schneeweiss, A., & Müller, V. (2019). Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. GEBURTSH FRAUENHEILK, 79(10), 1079-1089. https://doi.org/10.1055/a-1001-9925

Vancouver

Schütz F, Fasching PA, Welslau M, Hartkopf AD, Wöckel A, Lux MP et al. Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. GEBURTSH FRAUENHEILK. 2019 Okt;79(10):1079-1089. https://doi.org/10.1055/a-1001-9925

Bibtex

@article{2c36430efc0a44e2b90c771f16253dbf,
title = "Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer",
abstract = "The further development of therapies for women with early breast cancer is progressing far more slowly than in the case of patients with advanced breast cancer and is additionally delayed compared to developments in metastatic breast cancer. Nonetheless, significant advancements have been able to be recorded recently. This review summarises the latest developments in view of the most recent publications and professional conferences. For hormone-receptor-positive patients, new aspects for the duration of antihormone therapy and with regard to the benefits of multigene tests have been published. In the case of HER2-positive patients, the value of post-neoadjuvant therapy and de-escalation of the therapy is discussed. In patients with triple-negative breast cancer, there is a question of whether the knowledge of the biological background of a homologous recombination deficiency (HRD) helps develop new therapies for this subtype. In particular the {"}use{"} of a BRCA1/2 mutation or the biological characteristic HRD as a potential motive for therapy plays a role here in specifying the significance of platinum therapy and therapy with PARP inhibitors.",
author = "Florian Sch{\"u}tz and Fasching, {Peter A} and Manfred Welslau and Hartkopf, {Andreas D} and Achim W{\"o}ckel and Lux, {Michael P} and Wolfgang Janni and Johannes Ettl and Diana L{\"u}ftner and Erik Belleville and Hans-Christian Kolberg and Friedrich Overkamp and Florin-Andrei Taran and Brucker, {Sara Y} and Markus Wallwiener and Hans Tesch and Fehm, {Tanja N} and Andreas Schneeweiss and Volkmar M{\"u}ller",
year = "2019",
month = oct,
doi = "10.1055/a-1001-9925",
language = "English",
volume = "79",
pages = "1079--1089",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "10",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer

AU - Schütz, Florian

AU - Fasching, Peter A

AU - Welslau, Manfred

AU - Hartkopf, Andreas D

AU - Wöckel, Achim

AU - Lux, Michael P

AU - Janni, Wolfgang

AU - Ettl, Johannes

AU - Lüftner, Diana

AU - Belleville, Erik

AU - Kolberg, Hans-Christian

AU - Overkamp, Friedrich

AU - Taran, Florin-Andrei

AU - Brucker, Sara Y

AU - Wallwiener, Markus

AU - Tesch, Hans

AU - Fehm, Tanja N

AU - Schneeweiss, Andreas

AU - Müller, Volkmar

PY - 2019/10

Y1 - 2019/10

N2 - The further development of therapies for women with early breast cancer is progressing far more slowly than in the case of patients with advanced breast cancer and is additionally delayed compared to developments in metastatic breast cancer. Nonetheless, significant advancements have been able to be recorded recently. This review summarises the latest developments in view of the most recent publications and professional conferences. For hormone-receptor-positive patients, new aspects for the duration of antihormone therapy and with regard to the benefits of multigene tests have been published. In the case of HER2-positive patients, the value of post-neoadjuvant therapy and de-escalation of the therapy is discussed. In patients with triple-negative breast cancer, there is a question of whether the knowledge of the biological background of a homologous recombination deficiency (HRD) helps develop new therapies for this subtype. In particular the "use" of a BRCA1/2 mutation or the biological characteristic HRD as a potential motive for therapy plays a role here in specifying the significance of platinum therapy and therapy with PARP inhibitors.

AB - The further development of therapies for women with early breast cancer is progressing far more slowly than in the case of patients with advanced breast cancer and is additionally delayed compared to developments in metastatic breast cancer. Nonetheless, significant advancements have been able to be recorded recently. This review summarises the latest developments in view of the most recent publications and professional conferences. For hormone-receptor-positive patients, new aspects for the duration of antihormone therapy and with regard to the benefits of multigene tests have been published. In the case of HER2-positive patients, the value of post-neoadjuvant therapy and de-escalation of the therapy is discussed. In patients with triple-negative breast cancer, there is a question of whether the knowledge of the biological background of a homologous recombination deficiency (HRD) helps develop new therapies for this subtype. In particular the "use" of a BRCA1/2 mutation or the biological characteristic HRD as a potential motive for therapy plays a role here in specifying the significance of platinum therapy and therapy with PARP inhibitors.

U2 - 10.1055/a-1001-9925

DO - 10.1055/a-1001-9925

M3 - SCORING: Journal article

C2 - 31656318

VL - 79

SP - 1079

EP - 1089

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 10

ER -